Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ceplene, when administered in conjunction with low-dose interleukin-2 (IL-2), provides durable protection from leukemia relapse in patients with Acute Myeloid Leukemia.
Subscribe to our email newsletter
These data will be presented on June 6, 2009 at the European Hematology Association’s (EHA) 14th Congress in Berlin, Germany.
Researchers analyzed follow up data from patients enrolled in the phase III trial of Ceplene. The study found that the Ceplene/IL-2 treatment group continued to show statistically significant differences in LFS in the overall treatment population (p=0.011) and among the CR1 group (p=0.015).
Jack Talley, President and CEO of EpiCept, said: “These data provide further demonstration of the positive and prolonged clinical benefits Ceplene can provide AML patients in preventing relapse of this deadly disease.”
“These findings also represent the latest in a number of significant milestones for Ceplene, as we just announced that the drug is now available to patients in major markets throughout the world through our named patient program agreement with IDIS. We continue to be keenly focused on further expanding the extraordinary impact that Ceplene can have on AML patients through our regulatory advancement of the drug in North America,” he added.